Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Summary not available.
Scholar Rock (NASDAQ: SRRK) will present at three investor conferences in March 2026 via fireside chats and webcasts. Management will speak at TD Cowen on March 4, 2026 (1:50 p.m. ET, Boston), Leerink on March 10, 2026 (2:30 p.m. ET, Miami) and Barclays on March 12, 2026 (8:30 a.m. ET, Miami).
A live webcast will be available on the company Investors > Events and Presentations page, and replays will remain accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 114,668 shares to seven new hires: 64,226 inducement options and 50,442 inducement restricted stock units. The options carry an exercise price of $47.85, equal to the closing price on February 9, 2026.
Vesting: options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments. Awards are issued under the company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4) and are subject to standard service-based vesting conditions.
Scholar Rock (NASDAQ: SRRK) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before markets open. Management will host a conference call and live webcast at 8:00 a.m. ET.
Access the live audio webcast via the Investors "Events and Presentations" page on the Scholar Rock website. Telephone participants must register in advance and will receive a confirmation email with dial‑in instructions. An archived replay will be available on the company website for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards to two newly hired employees covering an aggregate of 35,200 shares of common stock: inducement stock options for 20,400 shares and inducement restricted stock units for 14,800 shares.
The options have an exercise price of $43.56, equal to the closing price on January 12, 2026. Options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 12 equal quarterly installments. RSUs vest in four equal annual installments. All vesting is conditioned on continued service and the awards are issued under the Company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) outlined 2026 priorities focused on regulatory approvals and commercialization of apitegromab for children and adults with spinal muscular atrophy (SMA). The company expects a BLA resubmission and U.S. launch in 2026 following FDA interactions and remediation work at a Catalent fill-finish site, and an EMA decision expected mid-2026. Apitegromab development includes a Phase 2 OPAL trial in 2-year-old patients and a planned Phase 2 FORGE trial in FSHD (IND cleared) starting mid-2026. SRK-439 and subcutaneous apitegromab programs are advancing; SRK-439 topline data expected H2 2026. Cash of approximately
Scholar Rock (NASDAQ: SRRK) said management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 7:30 a.m. PST (10:30 a.m. EST).
A live webcast will be available on the company’s Investors > Events and Presentations page at http://investors.scholarrock.com, and a replay will be accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards totaling 7,800 shares to two newly hired employees on December 13, 2025. The package comprises inducement stock options for 4,457 shares and inducement restricted stock units for 3,343 shares, issued under the Company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement options have an exercise price of $45.25 (equal to the closing price on December 8, 2025). Option vesting: 25% on first anniversary of each start date, then the remaining 75% in 12 equal quarterly installments. RSU vesting: four equal annual installments. All vesting is subject to continued employment.
Scholar Rock (NASDAQ: SRRK) reported third quarter 2025 results and program updates on November 14, 2025. The company completed an in-person Type A meeting with the FDA on November 12 regarding the apitegromab BLA and expects to resubmit and aim for a U.S. launch following approval in 2026. Catalent (Novo Nordisk) reported remediation progress and expects reinspection readiness by year-end 2025. Scholar Rock accelerated U.S. fill-finish capacity with tech transfer and commercial capacity reserved beginning Q1 2026. Dosing began in the Phase 2 OPAL study in infants/toddlers; EMA review expected by mid-2026. SRK-439 IND cleared and dosing in healthy volunteers expected in Q4 2025. Cash and marketable securities totaled $369.6M at September 30, 2025, expected to fund operations into 2027.
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards granted to one newly hired employee on November 12, 2025. The awards total 30,000 shares comprised of 17,143 stock options and 12,857 restricted stock units under the company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $29.37 (equal to the Nov 10, 2025 closing price). Option vesting: 25% after one year then quarterly over three years; RSU vesting: four equal annual installments. Vesting is conditioned on continuing service.